Employing Extracellular Volume Cardiovascular Magnetic Resonance Measures of Myocardial Fibrosis to Foster Novel Therapeutics

Circulation: Cardiovascular Imaging

Volumn 10, Issue 6, 2017, Pages

  Schelbert, Erik B ^a,b   Sabbah, Hani N ^c   Butler, Javed ^d   Gheorghiade, Mihai ^e  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^c HENRY FORD HEALTH SYSTEM   (United States)

^d STONY BROOK UNIVERSITY   (United States)

^e NORTHWESTERN UNIVERSITY   (United States)

Author keywords

cardiovascular magnetic resonance; extracellular matrix; extracellular volume fraction; heart failure; myocardial fibrosis; T1 mapping

Indexed keywords

ANTIFIBROTIC AGENT; CANDESARTAN; COLLAGEN; GADOLINIUM; LISINOPRIL; LOSARTAN; PERINDOPRIL; SERELAXIN; SPIRONOLACTONE; CARDIOVASCULAR AGENT; CONTRAST MEDIUM;

ADVERSE OUTCOME; ARTICLE; CARDIAC MUSCLE CELL; CARDIOVASCULAR MAGNETIC RESONANCE; COMPUTER ASSISTED TOMOGRAPHY; CONGESTIVE CARDIOMYOPATHY; EXTRACELLULAR MATRIX; EXTRACELLULAR SPACE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HEART MUSCLE FIBROSIS; HEART VENTRICLE REMODELING; HUMAN; HYPERTENSION; HYPERTROPHY; MICROVASCULATURE; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REMISSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; STATISTICAL ANALYSIS; ANIMAL; CARDIAC MUSCLE; CARDIOMYOPATHIES; DIAGNOSTIC IMAGING; DRUG EFFECTS; FIBROSIS; HEART FAILURE; IMAGE PROCESSING; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PATHOPHYSIOLOGY; PREDICTIVE VALUE; PROCEDURES; PROGNOSIS;

ANIMALS; CARDIOMYOPATHIES; CARDIOVASCULAR AGENTS; CONTRAST MEDIA; FIBROSIS; HEART FAILURE; HUMANS; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MYOCARDIUM; PREDICTIVE VALUE OF TESTS; PROGNOSIS; VENTRICULAR REMODELING;

EID: 85021854474     PISSN: 19419651     EISSN: 19420080     Source Type: Journal    
DOI: 10.1161/CIRCIMAGING.116.005619     Document Type: Article

References (125)

1. Weber KT, Brilla CG. Pathological hypertrophy and cardiac interstitium. Fibrosis and renin-angiotensin-aldosterone system. Circulation. 1991;83:1849-1865.
2. Swynghedauw B. Molecular mechanisms of myocardial remodeling. Physiol Rev. 1999;79:215-262.
3. Gheorghiade M, Larson CJ, Shah SJ, Greene SJ, Cleland JG, Colucci WS, Dunnmon P, Epstein SE, Kim RJ, Parsey RV, Stockbridge N, Carr J, Dinh W, Krahn T, Kramer F, Wahlander K, Deckelbaum LI, Crandall D, Okada S, Senni M, Sikora S, Sabbah HN, Butler J. Developing new treatments for heart failure: focus on the heart. Circ Heart Fail. 2016;9:e002727. doi: 10.1161/CIRCHEARTFAILURE.115.002727.
4. Wilcox JE, Fonarow GC, Ardehali H, Bonow RO, Butler J, Sauer AJ, Epstein SE, Khan SS, Kim RJ, Sabbah HN, Díez J, Gheorghiade M. "Targeting the heart" in heart failure: myocardial recovery in heart failure with reduced ejection fraction. JACC Heart Fail. 2015;3:661-669. doi: 10.1016/j.jchf.2015.04.011.
5. Shah SJ, Kitzman DW, Borlaug BA, van Heerebeek L, Zile MR, Kass DA, Paulus WJ. Phenotype-specific treatment of heart failure with preserved ejection fraction: a multiorgan roadmap. Circulation. 2016;134:73-90. doi: 10.1161/CIRCULATIONAHA.116.021884.
6. Schelbert EB, Wong TC, Gheorghiade M. Think small and examine the constituents of left ventricular hypertrophy and heart failure: cardiomyocytes versus fibroblasts, collagen, and capillaries in the interstitium. J Am Heart Assoc. 2015;4:e002491. doi: 10.1161/JAHA.115.002491.
7. Schelbert EB, Piehler KM, Zareba KM, Moon JC, Ugander M, Messroghli DR, Valeti US, Chang CH, Shroff SG, Diez J, Miller CA, Schmitt M, Kellman P, Butler J, Gheorghiade M, Wong TC. Myocardial fibrosis quantified by extracellular volume is associated with subsequent hospitalization for heart failure, death, or both across the spectrum of ejection fraction and heart failure stage. J Am Heart Assoc. 2015;4:e002613. doi: 10.1161/JAHA.115.002613.
8. Wong TC, Piehler KM, Kang IA, Kadakkal A, Kellman P, Schwartzman DS, Mulukutla SR, Simon MA, Shroff SG, Kuller LH, Schelbert EB. Myocardial extracellular volume fraction quantified by cardiovascular magnetic resonance is increased in diabetes and associated with mortality and incident heart failure admission. Eur Heart J. 2014;35:657-664. doi: 10.1093/eurheartj/eht193.
9. Wong TC, Piehler K, Meier CG, Testa SM, Klock AM, Aneizi AA, Shakesprere J, Kellman P, Shroff SG, Schwartzman DS, Mulukutla SR, Simon MA, Schelbert EB. Association between extracellular matrix expansion quantified by cardiovascular magnetic resonance and short-term mortality. Circulation. 2012;126:1206-1216. doi: 10.1161/ CIRCULATIONAHA.111.089409.
10. Ghosn MG, Pickett S, Brunner G, Nabi F, Zoghbi W, Quinones M, Nambi V, Shah D. Association of myocardial extracellular volume and clinical outcome: a cardiac magnetic resonance study (Abstract). J Am Coll Cardiol. 2015;65:A1077. doi: 10.1016/S0735-1097(15)61077-4.
11. Duca F, Zotter-Tufaro C, Kammerlander AA, Panzenböck A, Aschauer S, Dalos D, Köll B, Börries B, Agis H, Kain R, Aumayr K, Klinglmüller F, Mascherbauer J, Bonderman D. Cardiac extracellular matrix is associated with adverse outcome in patients with chronic heart failure. Eur J Heart Fail. 2017;19:502-511. doi: 10.1002/ejhf.680.
12. Aoki T, Fukumoto Y, Sugimura K, Oikawa M, Satoh K, Nakano M, Nakayama M, Shimokawa H. Prognostic impact of myocardial interstitial fibrosis in non-ischemic heart failure. Comparison between preserved and reduced ejection fraction heart failure. Circ J. 2011;75:2605-2613.
13. Duca F, Kammerlander AA, Zotter-Tufaro C, Aschauer S, Schwaiger ML, Marzluf BA, Bonderman D, Mascherbauer J. Interstitial fibrosis, functional status, and outcomes in heart failure with preserved ejection fraction: insights from a Prospective Cardiac Magnetic Resonance Imaging Study. Circ Cardiovasc Imaging. 2016;9:e005277. doi: 10.1161/ CIRCIMAGING.116.005277.
14. Schwartzkopff B, Brehm M, Mundhenke M, Strauer BE. Repair of coronary arterioles after treatment with perindopril in hypertensive heart disease. Hypertension. 2000;36:220-225.
15. Brilla CG, Funck RC, Rupp H. Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease. Circulation. 2000;102:1388-1393.
16. Izawa H, Murohara T, Nagata K, Isobe S, Asano H, Amano T, Ichihara S, Kato T, Ohshima S, Murase Y, Iino S, Obata K, Noda A, Okumura K, Yokota M. Mineralocorticoid receptor antagonism ameliorates left ventricular diastolic dysfunction and myocardial fibrosis in mildly symptomatic patients with idiopathic dilated cardiomyopathy: a pilot study. Circulation. 2005;112:2940-2945. doi: 10.1161/ CIRCULATIONAHA.105.571653.
17. Díez J, Querejeta R, López B, González A, Larman M, Martínez Ubago JL. Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients. Circulation. 2002;105:2512-2517.
18. Heydari B, Abdullah S, Pottala JV, Shah R, Abbasi S, Mandry D, Francis SA, Lumish H, Ghoshhajra BB, Hoffmann U, Appelbaum E, Feng JH, Blankstein R, Steigner M, McConnell JP, Harris W, Antman EM, Jerosch-Herold M, Kwong RY. Effect of omega-3 acid ethyl esters on left ventricular remodeling after acute myocardial infarction: The OMEGAREMODEL randomized clinical trial. Circulation. 2016;134:378-391. doi: 10.1161/CIRCULATIONAHA.115.019949.
19. Zannad F, Alla F, Dousset B, Perez A, Pitt B. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the randomized aldactone evaluation study (RALES). Rales Investigators. Circulation. 2000;102:2700-2706.
20. Thum T, Gross C, Fiedler J, Fischer T, Kissler S, Bussen M, Galuppo P, Just S, Rottbauer W, Frantz S, Castoldi M, Soutschek J, Koteliansky V, Rosenwald A, Basson MA, Licht JD, Pena JT, Rouhanifard SH, Muckenthaler MU, Tuschl T, Martin GR, Bauersachs J, Engelhardt S. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature. 2008;456:980-984. doi: 10.1038/ nature07511.
21. Bull S, White SK, Piechnik SK, Flett AS, Ferreira VM, Loudon M, Francis JM, Karamitsos TD, Prendergast BD, Robson MD, Neubauer S, Moon JC, Myerson SG. Human non-contrast T1 values and correlation with histology in diffuse fibrosis. Heart. 2013;99:932-937. doi: 10.1136/ heartjnl-2012-303052.
22. Kockova R, Kacer P, Pirk J, Maly J, Sukupova L, Sikula V, Kotrc M, Barciakova L, Honsova E, Maly M, Kautzner J, Sedmera D, Penicka M. Native T1 relaxation time and extracellular volume fraction as accurate markers of diffuse myocardial fibrosis in heart valve disease-comparison with targeted left ventricular myocardial biopsy. Circ J. 2016;80:1202-1209. doi: 10.1253/circj.CJ-15-1309.
23. Miller CA, Naish JH, Bishop P, Coutts G, Clark D, Zhao S, Ray SG, Yonan N, Williams SG, Flett AS, Moon JC, Greiser A, Parker GJ, Schmitt M. Comprehensive validation of cardiovascular magnetic resonance techniques for the assessment of myocardial extracellular volume. Circ Cardiovasc Imaging. 2013;6:373-383. doi: 10.1161/ CIRCIMAGING.112.000192.
24. de Meester de Ravenstein C, Bouzin C, Lazam S, Boulif J, Amzulescu M, Melchior J, Pasquet A, Vancraeynest D, Pouleur AC, Vanoverschelde JL, Gerber BL. Histological Validation of measurement of diffuse interstitial myocardial fibrosis by myocardial extravascular volume fraction from Modified Look-Locker imaging (MOLLI) T1 mapping at 3 T. J Cardiovasc Magn Reson. 2015;17:48. doi: 10.1186/s12968-015-0150-0.
25. Inui K, Tachi M, Saito T, Kubota Y, Murai K, Kato K, Takano H, Amano Y, Asai K, Shimizu W. Superiority of the extracellular volume fraction over the myocardial T1 value for the assessment of myocardial fibrosis in patients with non-ischemic cardiomyopathy. Magn Reson Imaging. 2016;34:1141-1145. doi: 10.1016/j.mri.2016.05.008.
26. Ide S, Riesenkampff E, Chiasson DA, Dipchand AI, Kantor PF, Chaturvedi RR, Yoo SJ, Grosse-Wortmann L. Histological validation of cardiovascular magnetic resonance T1 mapping markers of myocardial fibrosis in paediatric heart transplant recipients. J Cardiovasc Magn Reson. 2017;19:10. doi: 10.1186/s12968-017-0326-x.
27. Iles L, Pfluger H, Phrommintikul A, Cherayath J, Aksit P, Gupta SN, Kaye DM, Taylor AJ. Evaluation of diffuse myocardial fibrosis in heart failure with cardiac magnetic resonance contrast-enhanced T1 mapping. J Am Coll Cardiol. 2008;52:1574-1580. doi: 10.1016/j.jacc.2008.06.049.
28. Sibley CT, Noureldin RA, Gai N, Nacif MS, Liu S, Turkbey EB, Mudd JO, van der Geest RJ, Lima JA, Halushka MK, Bluemke DA. T1 Mapping in cardiomyopathy at cardiac MR: comparison with endomyocardial biopsy. Radiology. 2012;265:724-732. doi: 10.1148/radiol.12112721.
29. White SK, Sado DM, Fontana M, Banypersad SM, Maestrini V, Flett AS, Piechnik SK, Robson MD, Hausenloy DJ, Sheikh AM, Hawkins PN, Moon JC. T1 mapping for myocardial extracellular volume measurement by CMR: bolus only versus primed infusion technique. JACC Cardiovasc Imaging. 2013;6:955-962. doi: 10.1016/j.jcmg.2013.01.011.
30. Moon JC, Messroghli DR, Kellman P, Piechnik SK, Robson MD, Ugander M, Gatehouse PD, Arai AE, Friedrich MG, Neubauer S, Schulz-Menger J, Schelbert EB; Society for Cardiovascular Magnetic Resonance Imaging; Cardiovascular Magnetic Resonance Working Group of the European Society of Cardiology. Myocardial T1 mapping and extracellular volume quantification: a Society for Cardiovascular Magnetic Resonance (SCMR) and CMR Working Group of the European Society of Cardiology consensus statement. J Cardiovasc Magn Reson. 2013;15:92. doi: 10.1186/1532-429X-15-92.
31. Jerosch-Herold M, Sheridan DC, Kushner JD, Nauman D, Burgess D, Dutton D, Alharethi R, Li D, Hershberger RE. Cardiac magnetic resonance imaging of myocardial contrast uptake and blood flow in patients affected with idiopathic or familial dilated cardiomyopathy. Am J Physiol Heart Circ Physiol. 2008;295:H1234-H1242. doi: 10.1152/ ajpheart.00429.2008.
32. Mohammed SF, Hussain S, Mirzoyev SA, Edwards WD, Maleszewski JJ, Redfield MM. Coronary microvascular rarefaction and myocardial fibrosis in heart failure with preserved ejection fraction. Circulation. 2015;131:550-559. doi: 10.1161/CIRCULATIONAHA.114.009625.
33. Flett AS, Hayward MP, Ashworth MT, Hansen MS, Taylor AM, Elliott PM, McGregor C, Moon JC. Equilibrium contrast cardiovascular magnetic resonance for the measurement of diffuse myocardial fibrosis: preliminary validation in humans. Circulation. 2010;122:138-144. doi: 10.1161/CIRCULATIONAHA.109.930636.
34. aus dem Siepen F, Buss SJ, Messroghli D, Andre F, Lossnitzer D, Seitz S, Keller M, Schnabel PA, Giannitsis E, Korosoglou G, Katus HA, Steen H. T1 mapping in dilated cardiomyopathy with cardiac magnetic resonance: quantification of diffuse myocardial fibrosis and comparison with endomyocardial biopsy. Eur Heart J Cardiovasc Imaging. 2015;16:210-216. doi: 10.1093/ehjci/jeu183.
35. Fontana M, White SK, Banypersad SM, Sado DM, Maestrini V, Flett AS, Piechnik SK, Neubauer S, Roberts N, Moon JC. Comparison of T1 mapping techniques for ECV quantification. Histological validation and reproducibility of ShMOLLI versus multibreath-hold T1 quantification equilibrium contrast CMR. J Cardiovasc Magn Reson. 2012;14:88. doi: 10.1186/1532-429X-14-88.
36. Zeng M, Zhang N, He Y, Wen Z, Wang Z, Zhao Y, Greiser A, An J, Zhang T, Jing B, Zhang X, Fan Z, Li D. Histological validation of cardiac magnetic resonance T1 mapping for detecting diffuse myocardial fibrosis in diabetic rabbits. J Magn Reson Imaging. 2016;44:1179-1185. doi: 10.1002/jmri.25268.
37. McDiarmid AK, Swoboda PP, Erhayiem B, Ripley DP, Kidambi A, Broadbent DA, Higgins DM, Greenwood JP, Plein S. Single bolus versus split dose gadolinium administration in extra-cellular volume calculation at 3 Tesla. J Cardiovasc Magn Reson. 2015;17:6. doi: 10.1186/ s12968-015-0112-6.
38. Schelbert EB, Testa SM, Meier CG, Ceyrolles WJ, Levenson JE, Blair AJ, Kellman P, Jones BL, Ludwig DR, Schwartzman D, Shroff SG, Wong TC. Myocardial extravascular extracellular volume fraction measurement by gadolinium cardiovascular magnetic resonance in humans: slow infusion versus bolus. J Cardiovasc Magn Reson. 2011;13:16. doi: 10.1186/1532-429X-13-16.
39. Kawel N, Nacif M, Zavodni A, Jones J, Liu S, Sibley CT, Bluemke DA. T1 mapping of the myocardium: intra-individual assessment of postcontrast T1 time evolution and extracellular volume fraction at 3T for Gd-DTPA and Gd-BOPTA. J Cardiovasc Magn Reson. 2012;14:26. doi: 10.1186/1532-429X-14-26.
40. Chin CW, Semple S, Malley T, White AC, Mirsadraee S, Weale PJ, Prasad S, Newby DE, Dweck MR. Optimization and comparison of myocardial T1 techniques at 3T in patients with aortic stenosis. Eur Heart J Cardiovasc Imaging. 2014;15:556-565. doi: 10.1093/ehjci/jet245.
41. Singh A, Horsfield MA, Bekele S, Khan JN, Greiser A, McCann GP. Myocardial T1 and extracellular volume fraction measurement in asymptomatic patients with aortic stenosis: reproducibility and comparison with age-matched controls. Eur Heart J Cardiovasc Imaging. 2015;16:763-770. doi: 10.1093/ehjci/jev007.
42. Liu S, Han J, Nacif MS, Jones J, Kawel N, Kellman P, Sibley CT, Bluemke DA. Diffuse myocardial fibrosis evaluation using cardiac magnetic resonance T1 mapping: sample size considerations for clinical trials. J Cardiovasc Magn Reson. 2012;14:90. doi: 10.1186/1532-429X-14-90.
43. Treibel TA, Fridman Y, Hackman B, Kadakkal A, Sayeed A, Maanja M, Abu Daya H, Moon JC, Wong TC, Schelbert EB. Extracellular volume associates with outcomes more strongly than native or post-contrast myocardial T1. Eur Heart J Cardiovasc Imaging Supplement. 2016;17:i1-i80.
44. Rommel KP, von Roeder M, Latuscynski K, Oberueck C, Blazek S, Fengler K, Besler C, Sandri M, Lücke C, Gutberlet M, Linke A, Schuler G, Lurz P. Extracellular volume fraction for characterization of patients with heart failure and preserved ejection fraction. J Am Coll Cardiol. 2016;67:1815-1825. doi: 10.1016/j.jacc.2016.02.018.
45. Obokata M, Kane GC, Reddy YN, Olson TP, Melenovsky V, Borlaug BA. Role of diastolic stress testing in the evaluation for heart failure with preserved ejection fraction: a simultaneous invasive-echocardiographic study. Circulation. 2017;135:825-838. doi: 10.1161/ CIRCULATIONAHA.116.024822.
46. Sharifov OF, Schiros CG, Aban I, Denney TS, Gupta H. Diagnostic Accuracy of Tissue Doppler Index E/e' for Evaluating Left Ventricular Filling Pressure and Diastolic Dysfunction/Heart Failure With Preserved Ejection Fraction: A Systematic Review and Meta-Analysis. J Am Heart Assoc. 2016;5:e002530. doi: 10.1161/JAHA.115.002530.
47. Santos M, Rivero J, McCullough SD, West E, Opotowsky AR, Waxman AB, Systrom DM, Shah AM. E/e' ratio in patients with unexplained dyspnea: lack of accuracy in estimating left ventricular filling pressure. Circ Heart Fail. 2015;8:749-756. doi: 10.1161/ CIRCHEARTFAILURE.115.002161.
48. Nacif MS, Kawel N, Lee JJ, Chen X, Yao J, Zavodni A, Sibley CT, Lima JA, Liu S, Bluemke DA. Interstitial myocardial fibrosis assessed as extracellular volume fraction with low-radiation-dose cardiac CT. Radiology. 2012;264:876-883. doi: 10.1148/radiol.12112458.
49. Bandula S, White SK, Flett AS, Lawrence D, Pugliese F, Ashworth MT, Punwani S, Taylor SA, Moon JC. Measurement of myocardial extracellular volume fraction by using equilibrium contrast-enhanced CT: validation against histologic findings. Radiology. 2013;269:396-403. doi: 10.1148/radiol.13130130.
50. Nacif MS, Liu Y, Yao J, Liu S, Sibley CT, Summers RM, Bluemke DA. 3D left ventricular extracellular volume fraction by low-radiation dose cardiac CT: assessment of interstitial myocardial fibrosis. J Cardiovasc Comput Tomogr. 2013;7:51-57. doi: 10.1016/j.jcct.2012.10.010.
51. Kurita Y, Kitagawa K, Kurobe Y, Nakamori S, Nakajima H, Dohi K, Ito M, Sakuma H. Estimation of myocardial extracellular volume fraction with cardiac CT in subjects without clinical coronary artery disease: A feasibility study. J Cardiovasc Comput Tomogr. 2016;10:237-241. doi: 10.1016/j.jcct.2016.02.001.
52. Treibel TA, Fontana M, Steeden JA, Nasis A, Yeung J, White SK, Sivarajan S, Punwani S, Pugliese F, Taylor SA, Moon JC, Bandula S. Automatic quantification of the myocardial extracellular volume by cardiac computed tomography: Synthetic ECV by CCT. J Cardiovasc Comput Tomogr. 2017. doi: 10.1016/j.jcct.2017.02.006. Epub ahead of print.
53. Lee HJ, Im DJ, Youn JC, Chang S, Suh YJ, Hong YJ, Kim YJ, Hur J, Choi BW. Myocardial extracellular volume fraction with dual-energy equilibrium contrast-enhanced cardiac CT in nonischemic cardiomyopathy: a prospective comparison with cardiac MR imaging. Radiology. 2016;280:49-57. doi: 10.1148/radiol.2016151289.
54. Lee JJ, Liu S, Nacif MS, Ugander M, Han J, Kawel N, Sibley CT, Kellman P, Arai AE, Bluemke DA. Myocardial T1 and extracellular volume fraction mapping at 3 tesla. J Cardiovasc Magn Reson. 2011;13:75. doi: 10.1186/1532-429X-13-75.
55. Treibel TA, Fontana M, Maestrini V, Castelletti S, Rosmini S, Simpson J, Nasis A, Bhuva AN, Bulluck H, Abdel-Gadir A, White SK, Manisty C, Spottiswoode BS, Wong TC, Piechnik SK, Kellman P, Robson MD, Schelbert EB, Moon JC. Automatic Measurement of the Myocardial Interstitium: Synthetic Extracellular Volume Quantification Without Hematocrit Sampling. JACC Cardiovasc Imaging. 2016;9:54-63. doi: 10.1016/j.jcmg.2015.11.008.
56. Fent GJ, Garg P, Foley JR, Swoboda PP, Dobson LE, Erhayiem B, Greenwood JP, Plein S, Treibel TA, Moon JC. Synthetic myocardial extracellular volume fraction [published online ahead of print February 9, 2017]. JACC Cardiovasc Imaging. 2017. doi: 10.1016/j. jcmg.2016.12.007.
57. Messroghli DR, Radjenovic A, Kozerke S, Higgins DM, Sivananthan MU, Ridgway JP. Modified Look-Locker inversion recovery (MOLLI) for high-resolution T1 mapping of the heart. Magn Reson Med. 2004;52:141-146. doi: 10.1002/mrm.20110.
58. Roujol S, Weingärtner S, Foppa M, Chow K, Kawaji K, Ngo LH, Kellman P, Manning WJ, Thompson RB, Nezafat R. Accuracy, precision, and reproducibility of four T1 mapping sequences: a head-to-head comparison of MOLLI, ShMOLLI, SASHA, and SAPPHIRE. Radiology. 2014;272:683-689. doi: 10.1148/radiol.14140296.
59. Piechnik SK, Ferreira VM, Dall'Armellina E, Cochlin LE, Greiser A, Neubauer S, Robson MD. Shortened Modified Look-Locker Inversion recovery (ShMOLLI) for clinical myocardial T1-mapping at 1.5 and 3 T within a 9 heartbeat breathhold. J Cardiovasc Magn Reson. 2010;12:69. doi: 10.1186/1532-429X-12-69.
60. Chow K, Flewitt JA, Green JD, Pagano JJ, Friedrich MG, Thompson RB. Saturation recovery single-shot acquisition (SASHA) for myocardial T(1) mapping. Magn Reson Med. 2014;71:2082-2095. doi: 10.1002/ mrm.24878.
61. Salerno M, Janardhanan R, Jiji RS, Brooks J, Adenaw N, Mehta B, Yang Y, Antkowiak P, Kramer CM, Epstein FH. Comparison of methods for determining the partition coefficient of gadolinium in the myocardium using T1 mapping. J Magn Reson Imaging. 2013;38:217-224. doi: 10.1002/jmri.23875.
62. Robson MD, Piechnik SK, Tunnicliffe EM, Neubauer S. T1 measurements in the human myocardium: the effects of magnetization transfer on the SASHA and MOLLI sequences. Magn Reson Med. 2013;70:664-670. doi: 10.1002/mrm.24867.
63. Messroghli DR, Greiser A, Fröhlich M, Dietz R, Schulz-Menger J. Optimization and validation of a fully-integrated pulse sequence for modified look-locker inversion-recovery (MOLLI) T1 mapping of the heart. J Magn Reson Imaging. 2007;26:1081-1086. doi: 10.1002/ jmri.21119.
64. Xue H, Greiser A, Zuehlsdorff S, Jolly MP, Guehring J, Arai AE, Kellman P. Phase-sensitive inversion recovery for myocardial T1 mapping with motion correction and parametric fitting. Magn Reson Med. 2013;69:1408-1420. doi: 10.1002/mrm.24385.
65. Xue H, Shah S, Greiser A, Guetter C, Littmann A, Jolly MP, Arai AE, Zuehlsdorff S, Guehring J, Kellman P. Motion correction for myocardial T1 mapping using image registration with synthetic image estimation. Magn Reson Med. 2012;67:1644-1655. doi: 10.1002/mrm.23153.
66. Kellman P, Arai AE, Xue H. T1 and extracellular volume mapping in the heart: estimation of error maps and the influence of noise on precision. J Cardiovasc Magn Reson. 2013;15:56. doi: 10.1186/1532-429X-15-56.
67. Kato S, Saito N, Kirigaya H, Gyotoku D, Iinuma N, Kusakawa Y, Iguchi K, Nakachi T, Fukui K, Futaki M, Iwasawa T, Kimura K, Umemura S. Impairment of coronary flow reserve evaluated by phase contrast cinemagnetic resonance imaging in patients with heart failure with preserved ejection fraction. J Am Heart Assoc. 2016;5:e002649. doi: 10.1161/ JAHA.115.002649.
68. Brilla CG, Janicki JS, Weber KT. Cardioreparative effects of lisinopril in rats with genetic hypertension and left ventricular hypertrophy. Circulation. 1991;83:1771-1779.
69. Sabbah HN, Sharov VG, Lesch M, Goldstein S. Progression of heart failure: a role for interstitial fibrosis. Mol Cell Biochem. 1995;147:29-34.
70. Sabbah HN. Apoptotic cell death in heart failure. Cardiovasc Res. 2000;45:704-712.
71. Zile MR, Baicu CF, Ikonomidis JS, Stroud RE, Nietert PJ, Bradshaw AD, Slater R, Palmer BM, Van Buren P, Meyer M, Redfield MM, Bull DA, Granzier HL, LeWinter MM. Myocardial stiffness in patients with heart failure and a preserved ejection fraction: contributions of collagen and titin. Circulation. 2015;131:1247-1259. doi: 10.1161/ CIRCULATIONAHA.114.013215.
72. Tamarappoo BK, John BT, Reinier K, Teodorescu C, Uy-Evanado A, Gunson K, Jui J, Chugh SS. Vulnerable myocardial interstitium in patients with isolated left ventricular hypertrophy and sudden cardiac death: a postmortem histological evaluation. J Am Heart Assoc. 2012;1:e001511. doi: 10.1161/JAHA.112.001511.
73. Banypersad SM, Moon JC, Whelan C, Hawkins PN, Wechalekar AD. Updates in cardiac amyloidosis: a review. J Am Heart Assoc. 2012;1:e000364. doi: 10.1161/JAHA.111.000364.
74. Schelbert EB, Fonarow GC, Bonow RO, Butler J, Gheorghiade M. Therapeutic targets in heart failure: refocusing on the myocardial interstitium. J Am Coll Cardiol. 2014;63:2188-2198. doi: 10.1016/j. jacc.2014.01.068.
75. Neubauer S. The failing heart-an engine out of fuel. N Engl J Med. 2007;356:1140-1151. doi: 10.1056/NEJMra063052.
76. Ramires FJ, Mansur A, Coelho O, Maranhão M, Gruppi CJ, Mady C, Ramires JA. Effect of spironolactone on ventricular arrhythmias in congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy. Am J Cardiol. 2000;85:1207-1211.
77. Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med. 1999;341:709-717. doi: 10.1056/ NEJM199909023411001.
78. Pitt B, Remme W, Zannad F, Neaton J, Martinez F, Roniker B, Bittman R, Hurley S, Kleiman J, Gatlin M; Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 2003;348:1309-1321. doi: 10.1056/NEJMoa030207.
79. Silva JA Jr, Santana ET, Manchini MT, Antônio EL, Bocalini DS, Krieger JE, Tucci PJ, Serra AJ. Exercise training can prevent cardiac hypertrophy induced by sympathetic hyperactivity with modulation of kallikrein-kinin pathway and angiogenesis. PLoS One. 2014;9:e91017. doi: 10.1371/journal.pone.0091017.
80. Serra AJ, Higuchi ML, Ihara SS, Antônio EL, Santos MH, Bombig MT, Tucci PJ. Exercise training prevents beta-adrenergic hyperactivity-induced myocardial hypertrophy and lesions. Eur J Heart Fail. 2008;10:534-539. doi: 10.1016/j.ejheart.2008.03.016.
81. Silva E, Natali AJ, Silva MF, Gomes GJ, Cunha DN, Ramos RM, Toledo MM, Drummond FR, Belfort FG, Novaes RD, Maldonado IR. Ventricular remodeling in growing rats with experimental diabetes: The impact of swimming training. Pathol Res Pract. 2013;209:618-626. doi: 10.1016/j.prp.2013.06.009.
82. Hafstad AD, Lund J, Hadler-Olsen E, Höper AC, Larsen TS, Aasum E. High-and moderate-intensity training normalizes ventricular function and mechanoenergetics in mice with diet-induced obesity. Diabetes. 2013;62:2287-2294. doi: 10.2337/db12-1580.
83. Melo SF, Fernandes T, Baraúna VG, Matos KC, Santos AA, Tucci PJ, Oliveira EM. Expression of microRNA-29 and collagen in cardiac muscle after awimming training in myocardialiInfarcted rats. Cell Physiol Biochem. 2014;33:657-669. doi: 10.1159/000358642.
84. Samuel CS, Hewitson TD, Zhang Y, Kelly DJ. Relaxin ameliorates fibrosis in experimental diabetic cardiomyopathy. Endocrinology. 2008;149:3286-3293. doi: 10.1210/en.2008-0250.
85. Samuel CS, Bodaragama H, Chew JY, Widdop RE, Royce SG, Hewitson TD. Serelaxin is a more efficacious antifibrotic than enalapril in an experimental model of heart disease. Hypertension. 2014;64:315-322. doi: 10.1161/HYPERTENSIONAHA.114.03594.
86. Kolkhof P, Delbeck M, Kretschmer A, Steinke W, Hartmann E, Bärfacker L, Eitner F, Albrecht-Küpper B, Schäfer S. Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury. J Cardiovasc Pharmacol. 2014;64:69-78. doi: 10.1097/ FJC.0000000000000091.
87. Sabbah HN, Gupta RC, Kohli S, Wang M, Rastogi S, Zhang K, Zimmermann K, Diedrichs N, Albrecht-Küpper BE. Chronic therapy with a partial adenosine A1-receptor agonist improves left ventricular function and remodeling in dogs with advanced heart failure. Circ Heart Fail. 2013;6:563-571. doi: 10.1161/CIRCHEARTFAILURE.112.000208.
88. Jeong D, Lee MA, Li Y, Yang DK, Kho C, Oh JG, Hong G, Lee A, Song MH, LaRocca TJ, Chen J, Liang L, Mitsuyama S, D'Escamard V, Kovacic JC, Kwak TH, Hajjar RJ, Park WJ. Matricellular protein CCN5 reverses established cardiac fibrosis. J Am Coll Cardiol. 2016;67:1556-1568. doi: 10.1016/j.jacc.2016.01.030.
89. Banypersad SM, Fontana M, Maestrini V, Sado DM, Captur G, Petrie A, Piechnik SK, Whelan CJ, Herrey AS, Gillmore JD, Lachmann HJ, Wechalekar AD, Hawkins PN, Moon JC. T1 mapping and survival in systemic light-chain amyloidosis. Eur Heart J. 2015;36:244-251. doi: 10.1093/eurheartj/ehu444.
90. Weber KT, Diez J. Targeting the cardiac myofibroblast secretome to treat myocardial fibrosis in heart failure. Circ Heart Fail. 2016;9:e003315. doi: 10.1161/CIRCHEARTFAILURE.116.003315.
91. López B, Ravassa S, González A, Zubillaga E, Bonavila C, Bergés M, Echegaray K, Beaumont J, Moreno MU, San José G, Larman M, Querejeta R, Díez J. Myocardial collagen cross-linking is associated with heart failure hospitalization in patients with hypertensive heart failure. J Am Coll Cardiol. 2016;67:251-260. doi: 10.1016/j. jacc.2015.10.063.
92. Heymans S, González A, Pizard A, Papageorgiou AP, López-Andrés N, Jaisser F, Thum T, Zannad F, Díez J. Searching for new mechanisms of myocardial fibrosis with diagnostic and/or therapeutic potential. Eur J Heart Fail. 2015;17:764-771. doi: 10.1002/ejhf.312.
93. van Hoeven KH, Factor SM. A comparison of the pathological spectrum of hypertensive, diabetic, and hypertensive-diabetic heart disease. Circulation. 1990;82:848-855.
94. Tanaka M, Fujiwara H, Onodera T, Wu DJ, Hamashima Y, Kawai C. Quantitative analysis of myocardial fibrosis in normals, hypertensive hearts, and hypertrophic cardiomyopathy. Br Heart J. 1986;55:575-581.
95. Rossi MA. Pathologic fibrosis and connective tissue matrix in left ventricular hypertrophy due to chronic arterial hypertension in humans. J Hypertens. 1998;16:1031-1041.
96. Beltrami CA, Finato N, Rocco M, Feruglio GA, Puricelli C, Cigola E, Sonnenblick EH, Olivetti G, Anversa P. The cellular basis of dilated cardiomyopathy in humans. J Mol Cell Cardiol. 1995;27:291-305.
97. Ferreira VM, Wijesurendra RS, Liu A, Greiser A, Casadei B, Robson MD, Neubauer S, Piechnik SK. Systolic ShMOLLI myocardial T1-mapping for improved robustness to partial-volume effects and applications in tachyarrhythmias. J Cardiovasc Magn Reson. 2015;17:77. doi: 10.1186/s12968-015-0182-5.
98. Sado DM, Flett AS, Hasleton JM, Banypersad SM, White SK, Quarta G, Hawkins P, Pepys MB, Elliott PM, Moon JC. Myocardial interstitial expansion in health and disease-preliminary results from equilibrium contrast cardiovascular magnetic resonance (EQ-CMR). Eur Heart J. 2011;32(suppl 1):952 [abstract].
99. Fontana M, Pica S, Reant P, Abdel-Gadir A, Treibel TA, Banypersad SM, Maestrini V, Barcella W, Rosmini S, Bulluck H, Sayed RH, Patel K, Mamhood S, Bucciarelli-Ducci C, Whelan CJ, Herrey AS, Lachmann HJ, Wechalekar AD, Manisty CH, Schelbert EB, Kellman P, Gillmore JD, Hawkins PN, Moon JC. Prognostic Value of Late Gadolinium Enhancement Cardiovascular Magnetic Resonance in Cardiac Amyloidosis. Circulation. 2015;132:1570-1579. doi: 10.1161/ CIRCULATIONAHA.115.016567.
100. Verbrugge FH, Bertrand PB, Willems E, Gielen E, Mullens W, Giri S, Tang WH, Raman SV, Verhaert D. Global myocardial oedema in advanced decompensated heart failure. Eur Heart J Cardiovasc Imaging. 2016. doi: 10.1093/ehjci/jew131. Epub ahead of print.
101. Ugander M, Bagi PS, Oki AJ, Chen B, Hsu LY, Aletras AH, Shah S, Greiser A, Kellman P, Arai AE. Myocardial edema as detected by precontrast T1 and T2 CMR delineates area at risk associated with acute myocardial infarction. JACC Cardiovasc Imaging. 2012;5:596-603. doi: 10.1016/j.jcmg.2012.01.016.
102. Mahmod M, Piechnik SK, Levelt E, Ferreira VM, Francis JM, Lewis A, Pal N, Dass S, Ashrafian H, Neubauer S, Karamitsos TD. Adenosine stress native T1 mapping in severe aortic stenosis: evidence for a role of the intravascular compartment on myocardial T1 values. J Cardiovasc Magn Reson. 2014;16:92. doi: 10.1186/s12968-014-0092-y.
103. Liu A, Wijesurendra RS, Francis JM, Robson MD, Neubauer S, Piechnik SK, Ferreira VM. Adenosine stress and rest T1 mapping can differentiate between ischemic, infarcted, remote, and normal myocardium without the need for gadolinium contrast agents. JACC Cardiovasc Imaging. 2016;9:27-36. doi: 10.1016/j.jcmg.2015.08.018.
104. Beltrami CA, Finato N, Rocco M, Feruglio GA, Puricelli C, Cigola E, Quaini F, Sonnenblick EH, Olivetti G, Anversa P. Structural basis of end-stage failure in ischemic cardiomyopathy in humans. Circulation. 1994;89:151-163.
105. Moon JC, Treibel TA, Schelbert EB. Myocardial fibrosis in hypertensive heart failure: does quality rather than quantity matter? J Am Coll Cardiol. 2016;67:261-263. doi: 10.1016/j.jacc.2015.10.070.
106. Friedrich MG. There is more than shape and function. J Am Coll Cardiol. 2008;52:1581-1583. doi: 10.1016/j.jacc.2008.08.010.
107. Wong TC, Piehler KM, Kellman P, Schelbert EB. Extracellular matrix expansion is more strongly associated with cardiovascular outcomes than left ventricular mass. (Abstract). J Am Coll Cardiol. 2014;63:A986.
108. Swoboda PP, McDiarmid AK, Erhayiem B, Broadbent DA, Dobson LE, Garg P, Ferguson C, Page SP, Greenwood JP, Plein S. Assessing myocardial extracellular volume by T1 mapping to distinguish hypertrophic cardiomyopathy from Athlete's heart. J Am Coll Cardiol. 2016;67:2189-2190. doi: 10.1016/j.jacc.2016.02.054.
109. Shah SJ, Katz DH, Selvaraj S, Burke MA, Yancy CW, Gheorghiade M, Bonow RO, Huang CC, Deo RC. Phenomapping for novel classification of heart failure with preserved ejection fraction. Circulation. 2015;131:269-279. doi: 10.1161/CIRCULATIONAHA.114.010637.
110. Zile MR, Jhund PS, Baicu CF, Claggett BL, Pieske B, Voors AA, Prescott MF, Shi V, Lefkowitz M, McMurray JJ, Solomon SD. Plasma Biomarkers Reflecting Profibrotic Processes in Heart Failure With a Preserved Ejection Fraction: Data From the Prospective Comparison of ARNI With ARB on Management of Heart Failure With Preserved Ejection Fraction Study. Circ Heart Fail. 2016;9:e002551. doi: 10.1161/ CIRCHEARTFAILURE.115.002551.
111. Cleland JG, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J; PEP-CHF Investigators. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006;27:2338-2345. doi: 10.1093/eurheartj/ehl250.
112. Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, Anderson S, Donovan M, Iverson E, Staiger C, Ptaszynska A; I-PRESERVE Investigators. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008;359:2456-2467. doi: 10.1056/NEJMoa0805450.
113. Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003;362:777-781. doi: 10.1016/S0140-6736(03)14285-7.
114. Pfeffer MA, Claggett B, Assmann SF, Boineau R, Anand IS, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Heitner JF, Lewis EF, O'Meara E, Rouleau JL, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, McKinlay SM, Pitt B. Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial. Circulation. 2015;131:34-42. doi: 10.1161/CIRCULATIONAHA.114.013255.
115. Butler J, Fonarow GC, Zile MR, Lam CS, Roessig L, Schelbert EB, Shah SJ, Ahmed A, Bonow RO, Cleland JG, Cody RJ, Chioncel O, Collins SP, Dunnmon P, Filippatos G, Lefkowitz MP, Marti CN, McMurray JJ, Misselwitz F, Nodari S, O'Connor C, Pfeffer MA, Pieske B, Pitt B, Rosano G, Sabbah HN, Senni M, Solomon SD, Stockbridge N, Teerlink JR, Georgiopoulou VV, Gheorghiade M. Developing therapies for heart failure with preserved ejection fraction: current state and future directions. JACC Heart Fail. 2014;2:97-112. doi: 10.1016/j.jchf.2013.10.006.
116. van Heerebeek L, Borbély A, Niessen HW, Bronzwaer JG, van der Velden J, Stienen GJ, Linke WA, Laarman GJ, Paulus WJ. Myocardial structure and function differ in systolic and diastolic heart failure. Circulation. 2006;113:1966-1973. doi: 10.1161/CIRCULATIONAHA.105.587519.
117. Teerlink JR, Cotter G, Davison BA, Felker GM, Filippatos G, Greenberg BH, Ponikowski P, Unemori E, Voors AA, Adams KF Jr, Dorobantu MI, Grinfeld LR, Jondeau G, Marmor A, Masip J, Pang PS, Werdan K, Teichman SL, Trapani A, Bush CA, Saini R, Schumacher C, Severin TM, Metra M; RELAXin in Acute Heart Failure (RELAX-AHF) Investigators. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet. 2013;381:29-39. doi: 10.1016/S0140-6736(12)61855-8.
118. Lonn EM, Bosch J, López-Jaramillo P, Zhu J, Liu L, Pais P, Diaz R, Xavier D, Sliwa K, Dans A, Avezum A, Piegas LS, Keltai K, Keltai M, Chazova I, Peters RJ, Held C, Yusoff K, Lewis BS, Jansky P, Parkhomenko A, Khunti K, Toff WD, Reid CM, Varigos J, Leiter LA, Molina Di, McKelvie R, Pogue J, Wilkinson J, Jung H, Dagenais G, Yusuf S; HOPE-3 Investigators. Blood-pressure lowering in intermediate-risk persons without cardiovascular disease. N Engl J Med. 2016;374:2009-2020. doi: 10.1056/NEJMoa1600175.
119. Dahlöf B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H; LIFE Study Group. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet. 2002;359:995-1003. doi: 10.1016/ S0140-6736(02)08089-3.
120. Heart Outcomes Prevention Evaluation Study Investigators. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med. 2000;342:145-153
121. Geschka S, Kretschmer A, Sharkovska Y, Evgenov OV, Lawrenz B, Hucke A, Hocher B, Stasch JP. Soluble guanylate cyclase stimulation prevents fibrotic tissue remodeling and improves survival in saltsensitive Dahl rats. PLoS One. 2011;6:e21853. doi: 10.1371/journal. pone.0021853.
122. Lin JH, Zhang JJ, Lin SL, Chertow GM. Design of a phase 2 clinical trial of an ASK1 inhibitor, GS-4997, in patients with diabetic kidney disease. Nephron. 2015;129:29-33. doi: 10.1159/000369152.
123. Butler J, Fonarow GC, Gheorghiade M. Strategies and opportunities for drug development in heart failure. JAMA. 2013;309:1593-1594. doi: 10.1001/jama.2013.1063.
124. Wong TC, Schelbert EB. Many paths lead to CV outcomes: a potential need for image-guided precision medicine. JACC Cardiovasc Imaging. 2016;9:24-26. doi: 10.1016/j.jcmg.2015.11.006.
125. McLenachan JM, Dargie HJ. Ventricular arrhythmias in hypertensive left ventricular hypertrophy. Relationship to coronary artery disease, left ventricular dysfunction, and myocardial fibrosis. Am J Hypertens. 1990;3:735-740.